BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia 2020;34:2012-24. [PMID: 32457353 DOI: 10.1038/s41375-020-0873-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Minton A, Smith L, Bryant D, Strefford J, Forconi F, Stevenson F, Tumbarello D, James E, Løset G, Munthe L, Steele A, Packham G. B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00070] [Reference Citation Analysis]
2 Lyski ZL, Kim MS, Xthona Lee D, Sampson D, Raué HP, Raghunathan V, Ryan D, Brunton AE, Slifka MK, Messer WB, Spurgeon SE. Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. Case Rep Hematol 2022;2022:6831640. [PMID: 35127183 DOI: 10.1155/2022/6831640] [Reference Citation Analysis]
3 Lam V, Best S, Kittai A, Orand K, Spurgeon SE, Liu T, Danilov AV. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol 2021. [PMID: 34196037 DOI: 10.1111/bcp.14962] [Reference Citation Analysis]
4 Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3255. [PMID: 34209724 DOI: 10.3390/cancers13133255] [Reference Citation Analysis]
5 Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, Dorillo E, Rompietti C, Adamo FM, Ruggeri L, Di Ianni M, Rosati E. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int J Mol Sci 2021;22:6665. [PMID: 34206399 DOI: 10.3390/ijms22136665] [Reference Citation Analysis]
6 Puzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, Trentin L, Reda G, Cuneo A, Molica S, Piciocchi A, Arena V, Mauro FR, Guarini A, Foà R. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Front Oncol 2021;11:637186. [PMID: 33937038 DOI: 10.3389/fonc.2021.637186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio MTS, Ponzoni M, Casorati G, Dellabona P, Ghia P, Bellone M, Calcinotto A. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism. Blood Adv 2021;5:2817-28. [PMID: 34269799 DOI: 10.1182/bloodadvances.2020003795] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Capitani N, Patrussi L, Baldari CT. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. Int J Mol Sci 2021;22:11221. [PMID: 34681881 DOI: 10.3390/ijms222011221] [Reference Citation Analysis]
9 Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, Bücklein VL, Subklewe M. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. Front Immunol 2021;12:608625. [PMID: 33790890 DOI: 10.3389/fimmu.2021.608625] [Reference Citation Analysis]
10 Llaó-Cid L, Roessner PM, Chapaprieta V, Öztürk S, Roider T, Bordas M, Izcue A, Colomer D, Dietrich S, Stilgenbauer S, Hanna B, Martín-Subero JI, Seiffert M. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. Leukemia 2021. [PMID: 33731848 DOI: 10.1038/s41375-021-01198-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Trimech M, Letourneau A, Missiaglia E, De Prijck B, Nagy-Hulliger M, Somja J, Vivario M, Gaulard P, Lambert F, Bisig B, de Leval L. Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome. Am J Surg Pathol 2021;45:773-86. [PMID: 33739791 DOI: 10.1097/PAS.0000000000001646] [Reference Citation Analysis]
12 Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Front Immunol 2020;11:590072. [PMID: 33329575 DOI: 10.3389/fimmu.2020.590072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Front Immunol 2021;12:780442. [PMID: 34899742 DOI: 10.3389/fimmu.2021.780442] [Reference Citation Analysis]
14 Aydin E, Faehling S, Saleh M, Llaó Cid L, Seiffert M, Roessner PM. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors? Front Immunol 2020;11:595818. [PMID: 33552053 DOI: 10.3389/fimmu.2020.595818] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Öztürk S, Kalter V, Roessner PM, Sunbul M, Seiffert M. IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:1899. [PMID: 33920868 DOI: 10.3390/cancers13081899] [Reference Citation Analysis]
16 Danilov AV. Immunity in CLL: corrupt at inception? Blood 2022;139:2104-5. [PMID: 35389445 DOI: 10.1182/blood.2022015413] [Reference Citation Analysis]
17 Baptista MJ, Baskar S, Gaglione EM, Keyvanfar K, Ahn IE, Wiestner A, Sun C. Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clin Cancer Res 2021;27:4624-33. [PMID: 33875521 DOI: 10.1158/1078-0432.CCR-20-4894] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3856. [PMID: 34359757 DOI: 10.3390/cancers13153856] [Reference Citation Analysis]
19 Galigalidou C, Zaragoza-Infante L, Iatrou A, Chatzidimitriou A, Stamatopoulos K, Agathangelidis A. Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. Front Oncol 2021;11:769612. [PMID: 34858849 DOI: 10.3389/fonc.2021.769612] [Reference Citation Analysis]
20 Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol 2021. [PMID: 34699616 DOI: 10.1002/ajh.26388] [Reference Citation Analysis]
21 Kulumani Mahadevan LS, Ozdemirli M. Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia. BMJ Case Rep 2021;14:e243490. [PMID: 34580127 DOI: 10.1136/bcr-2021-243490] [Reference Citation Analysis]
22 Zhu X, Hu H, Xiao Y, Li Q, Zhong Z, Yang J, Zou P, Cao Y, Meng F, Li W, You Y, Guo AY, Zhu X. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. Cancer Lett 2022;536:215668. [PMID: 35367518 DOI: 10.1016/j.canlet.2022.215668] [Reference Citation Analysis]
23 Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Front Immunol 2020;11:594556. [PMID: 33312177 DOI: 10.3389/fimmu.2020.594556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lyski ZL, Kim S, Lee DX, Sampson D, Raué HP, Raghunathan V, Ryan D, Brunton AE, Slifka MK, Messer WB, Spurgeon SE. Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two CLL patients. medRxiv 2021:2021. [PMID: 34518841 DOI: 10.1101/2021.09.02.21262146] [Reference Citation Analysis]
25 Roessner PM, Llaó Cid L, Lupar E, Roider T, Bordas M, Schifflers C, Arseni L, Gaupel AC, Kilpert F, Krötschel M, Arnold SJ, Sellner L, Colomer D, Stilgenbauer S, Dietrich S, Lichter P, Izcue A, Seiffert M. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia 2021;35:2311-24. [PMID: 33526861 DOI: 10.1038/s41375-021-01136-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]